MELA-Indeed, derm's might use this to push MORE biopsies, rather than fewer, which would end up being a good thing for NGNM's melanoma genetics test coming on line early next year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.